Wall Street Zen Upgrades DBV Technologies (NASDAQ:DBVT) to “Hold”

DBV Technologies (NASDAQ:DBVT) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Friday.

DBVT has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price (up previously from $16.00) on shares of DBV Technologies in a research report on Wednesday, October 29th. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, DBV Technologies presently has an average rating of “Hold” and a consensus target price of $16.08.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $14.00 on Friday. The stock has a market capitalization of $503.52 million, a price-to-earnings ratio of -2.71 and a beta of -0.49. DBV Technologies has a one year low of $2.74 and a one year high of $18.00. The company’s 50-day simple moving average is $13.66 and its 200-day simple moving average is $11.01.

Institutional Trading of DBV Technologies

A number of large investors have recently modified their holdings of DBVT. Adage Capital Partners GP L.L.C. acquired a new stake in DBV Technologies in the 2nd quarter valued at approximately $9,659,000. Vivo Capital LLC bought a new stake in shares of DBV Technologies during the second quarter valued at about $9,659,000. MPM Bioimpact LLC acquired a new stake in DBV Technologies in the second quarter worth about $9,649,000. Octagon Capital Advisors LP acquired a new stake in DBV Technologies in the second quarter worth about $9,315,000. Finally, Millennium Management LLC grew its position in DBV Technologies by 26.1% in the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after buying an additional 69,849 shares in the last quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.